ARS Pharmaceuticals (NASDAQ: SPRY) has appointed Donn Casale as president, effective June 1, 2026, with Richard Lowenthal continuing to lead as CEO.
Mr. Casale brings 25 years of biopharmaceutical commercial leadership with extensive experience scaling innovative products in large consumer-driven healthcare markets. He most recently served as chief commercial officer at Dynavax Technologies—acquired by Sanofi (EURONEXT: SAN; NASDAQ: SNY)—where he built the U.S. commercial infrastructure and helped scale the hepatitis B vaccine HEPLISAV-B from launch to more than $300 million in annualized revenue and over 50 percent market share.
In a statement, Richard Lowenthal, co-founder and CEO of ARS, commented, “We are very pleased to welcome Donn to the ARS team, where he will play a key role in leading our commercial strategy for neffy (epinephrine nasal spray) and accelerating adoption and sales growth. Donn has built and led commercial organizations that successfully scaled innovative products in large, patient-driven markets similar to our own. His expertise in retail channel execution and payor access strategy will help further expand patient access and accelerate adoption of neffy, while also preparing ARS Pharma for its next phase of growth, including expansion into CSU. We look forward to the strategic perspective and leadership he will bring as we continue expanding access to lifesaving treatments for patients at risk of severe Type I allergic reactions.”
